Search

Displaying results 4611 - 4620 of 9333 in total
  1. Drug

    DYNE-251

    go.drugbank.com/drugs/DB18130
    Investigational

    DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). … It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.

  2. Drug

    N-Methylmesoporphyrin

    go.drugbank.com/drugs/DB01911
    Experimental

    This compound belongs to the porphyrins. … This medication is known to target ferrochelatase.

  3. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.

  4. Drug

    Paramethasone

    go.drugbank.com/drugs/DB01384
    Experimental

    A glucocorticoid with the general properties of corticosteroids. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p737)

  5. Drug

    Altretamine

    go.drugbank.com/drugs/DB00488
    ApprovedWithdrawn

    An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.

  6. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. … Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.

  7. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. … It is developed for the treatment of obesity and other metabolic disorders.

  8. Drug

    9-(4-hydroxybutyl)-N2-phenylguanine

    go.drugbank.com/drugs/DB02495
    Experimental

    This compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.

  9. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.

  10. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system. … Elafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or